| Cvs Pharmacy #02325 | |
| 1025 Central St, Stoughton, Massachusetts 02072 | |
| (781) 341-6114 |
| Name | Cvs Pharmacy #02325 |
|---|---|
| Organization Name | Cvs Pharmacy Inc |
| Location | 1025 Central St, Stoughton, Massachusetts 02072 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (781) 341-6114 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A call for ambulance workers to be allowed to use capsicum spray to protect them against violent and aggressive patients has evoked quite a mixed response across Australia.
Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the University of Otago in Christchurch, New Zealand and included patients admitted to Christchurch Hospital with acute decompensated heart failure.
A new University at Buffalo study of treatments for children with attention deficit hyperactivity disorder (ADHD) has found that combining behavior modification therapy with medication is the most effective way to improve the behavior of many ADHD children.
The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it reduced viral replication by as much as 96 percent in the animal study. Spearheaded by Public Health England's (PHE) Deputy Director, Professor Miles Carroll, the new study described the potential treatment and has been published in the open-source preprint server bioRxiv*.
› Verified 3 days ago
| NPI Number | 1396844692 |
| Organization Name | CVS PHARMACY INC |
| Doing Business As | CVS PHARMACY # 02325 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 1025 Central St, Stoughton, MA 02072 |
| Phone Number | 781-341-6114 |
News Archive
A call for ambulance workers to be allowed to use capsicum spray to protect them against violent and aggressive patients has evoked quite a mixed response across Australia.
Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the University of Otago in Christchurch, New Zealand and included patients admitted to Christchurch Hospital with acute decompensated heart failure.
A new University at Buffalo study of treatments for children with attention deficit hyperactivity disorder (ADHD) has found that combining behavior modification therapy with medication is the most effective way to improve the behavior of many ADHD children.
The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it reduced viral replication by as much as 96 percent in the animal study. Spearheaded by Public Health England's (PHE) Deputy Director, Professor Miles Carroll, the new study described the potential treatment and has been published in the open-source preprint server bioRxiv*.
› Verified 3 days ago
News Archive
A call for ambulance workers to be allowed to use capsicum spray to protect them against violent and aggressive patients has evoked quite a mixed response across Australia.
Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the University of Otago in Christchurch, New Zealand and included patients admitted to Christchurch Hospital with acute decompensated heart failure.
A new University at Buffalo study of treatments for children with attention deficit hyperactivity disorder (ADHD) has found that combining behavior modification therapy with medication is the most effective way to improve the behavior of many ADHD children.
The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it reduced viral replication by as much as 96 percent in the animal study. Spearheaded by Public Health England's (PHE) Deputy Director, Professor Miles Carroll, the new study described the potential treatment and has been published in the open-source preprint server bioRxiv*.
› Verified 3 days ago
All Care Home Health Srv Type: Durable Medical Equipment & Medical Supplies Supplier Location: 557 Park St, Stoughton, Massachusetts 02072 Phone: (781) 297-2002 | |
Boston Home Infusion Inc. Type: DME Supplier - Parenteral & Enteral Nutrition Location: 30 Buckley Rd, Stoughton, Massachusetts 02072 Phone: (866) 526-1297 | |
Cvs Pharmacy #02325 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1025 Central St, Stoughton, Massachusetts 02072 Phone: (781) 341-6114 | |
Cvs Pharmacy #17332 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1 Hawes Way, Stoughton, Massachusetts 02072 Phone: (781) 847-4003 | |
Walgreens #5755 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 413 Washington St, Stoughton, Massachusetts 02072 Phone: (781) 344-5600 |